Professor of Oncology @UniAvogadro & Medical Oncologist Head Division of Oncology Maggiore della Carità Hospital Novara IT #BreastCancer #MolecularImaging #IO
Genova, Liguria
Joined June 2019
- Tweets500
- Following423
- Followers929
- Likes793
Alessandra Gennari MD PhD retweeted
Are you ready for radioligand therapy? Join the next #ESMOOnAir webinar part of the Therapeutic Landscapes series:
- Science, clinical trials & system readiness for RLT
- Live expert Q&A
🔗 ow.ly/b4Es50XnBxm
#Oncology #Radiotheranostics #CancerCare #RLT #MedicalEducation
Alessandra Gennari MD PhD retweeted
Insieme alla cura dei pazienti e alla ricerca, la formazione dei giovani oncologi è una delle componenti più belle del nostro lavoro.
Quando il risultato sono eccellenze come Matteo Lambertini, si viene ripagati di tutto l’impegno e le energie investiti!
Ultima foto da #ESMO25 per ringraziare la persona speciale che mi ha fatto crescere in ambito professionale, che mi accompagna ancora oggi e che sicuramente continuerà a sostenermi in futuro…insomma, sempre #INSIEME a @delmastro_lucia 💪🙌😍🤩
@AIOMtweet @OncoAlert @UniGenova
Alessandra Gennari MD PhD retweeted
Absolutely AMAZING discussion by Ana Garrido-Castro on ASCENT-03 and TROPiON-Breast02!!!
@DFCI_BreastOnc #ESMO25 @OncoAlert
Alessandra Gennari MD PhD retweeted
What’s interesting is the control arm in post-Monarch (CDK46 inhibitor prior treatment) was fulvestrant alone w/ ~50% mutPIK3CA and had mPFS 5.3 months.
Sometimes it does help us compare how different populations of post-CDK4/6 inhibitor patients can be. #ESMO25
Excellent question from the audience.
Why in the world are we still using single agent fulvestrant control arms in 2025?
Apparently @US_FDA mandated this in Viktoria 1.
Alessandra Gennari MD PhD retweeted
#ESMO25: Positive phase III #ClinicalTrial data with T-DXd in high-risk, HER2+ #EarlyBreastCancer suggest that a paradigm change in the treatment of these patients may be imminent.
Read more in the #ESMODailyReporter 📌ow.ly/FvVq50XeuyE
#BreastCancer #ADC
@E_de_Azambuja
Alessandra Gennari MD PhD retweeted
Interesting news re: abemaciclib in MonarchE trial. At 5 years, the OS data in @JCO_ASCO was NS with HR 0.9.
Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients!
prnewswire.com/news-releases…
Alessandra Gennari MD PhD retweeted
La preservazione della fertilità è parte essenziale della cura in oncologia.
Grazie all’@ass_coscioni per aver dato spazio a questo tema, che riguarda il futuro di donne e uomini colpiti da tumore.
Parlare, informare, accompagnare: è anche questo prendersi cura.
Alessandra Gennari MD PhD retweeted
Onorata di intervenire a #ESCCardioOnco2025
La collaborazione tra diversi specialisti è un esempio concreto di quanto la multidisciplinarietà sia cruciale nella cura del cancro @escardio @AIOMtweet
#cardiooncology #collaborazione #oncologia #cardiologia #INSIEME
Alessandra Gennari MD PhD retweeted
Da oggi al 14 con @AIOMtweet @AiomFondazione @AIRC_it @_sirm saremo al Porto Antico del @ComunediGenova per parlare di #prevenzione in oncologia in occasione dell'arrivo del @tourvespucci
@delmastro_lucia @matteolambe @CarloGenova5 @Poggio_Fra @DSoldatoMD @boutrosand @UniGenova
Manca pochissimo all'ultima tappa del #tourvespucci: vi aspettiamo il 10 giugno a Genova.
#wearevespucci #prevenzione #fondazioneaiom
@tourvespucci
@AIRC_it
@_sirm
RT @PTarantinoMD: SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts…
Alessandra Gennari MD PhD retweeted
NEWS FROM INDUSTRY
Source AstraZeneca
astrazeneca.com/media-centre…
The Phase III DESTINY-Breast09 trial marks a significant advancement in HER2-positive metastatic #BreastCancer treatment, showing that trastuzumab deruxtecan combined with pertuzumab delivers a statistically significant and clinically meaningful improvement in PFS 🆚 the current 1st-line standard regimen of taxane, trastuzumab, and pertuzumab (THP). This is the first trial in over a decade to demonstrate superior efficacy across a broad HER2-positive metastatic population in the 1st-line setting. While OS data remain immature, early trends favor the Enhertu combination.
Ping OncoAlert Breast #Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @StoverLab @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel
#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
Alessandra Gennari MD PhD retweeted
📣ESMO Living Guidelines on Metastatic Breast Cancer:
👉Just updated with the latest recommendations and algorithms in an interactive format.
🔗ow.ly/loX750VBoN6
#ClinicalPracticeGuideline
Alessandra Gennari MD PhD retweeted
T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats @curijoey for leading the DB06 trial that backed this approval!
astrazeneca.com/media-centre…
Alessandra Gennari MD PhD retweeted
Important analyses. Thinking about treatment selection by actual prognosis/risk, and not by study eligibility, is a long standing approach in breast cancer. As was discussed @SG_BCC St Gallen last month, it should be applied to decision making in adjuvant CDK46i selection, too.
I want to thank all those have contributed, including all the investigators of MIG/GIM trials, all the patients included, and all co-authors, particularly @BlondeauxEva, @matteolambe and @delmastro_lucia for giving me the chance to conduct this analysis! 🤝
@OncoAlert
Alessandra Gennari MD PhD retweeted
Our Collaborators at @high5md are here in San Antonio bringing you LIVE Reports from #SABCS24 🇺🇸from TOP international Experts🌐in #BreastCancer
Find their Coverage here: high5oncology.tv/meeting-cov…
Experts include @hoperugo @curijoey @Prof_Nadia_H @ALEDIGNUS12 @stolaney1 and many more
Alessandra Gennari MD PhD retweeted
Just released the 2nd version of the @myESMO Essentials for Clinicians - Breast Cancer.
Honoured to have contributed w a chapter purely focused on BC in #young women.
Thanks to @matteolambe for this opportunity and to @myESMO editorial team for this effort!
@OncoAlert
Alessandra Gennari MD PhD retweeted
Oggi 13 maggio ⌚️ alle ore 14.00
I Laboratori dell’Oncologia di Domani: Molecular Tumor Board
Un Live Webinar con Responsabili Scientifici Proff. Alessandra Gennari e Valentina Guarneri.
Programma ed iscrizioni: overgroup.eu/evento/i-labora…
#MTB @ALEDIGNUS12
